Next Phase Newsletter

A Venture Capital firm with offices in the USA closed their first fund in 2014 and is currently working on their second fund. The firm has approximately 40 active investments in the biotech space. The firm mostly invests in Seed to Series B primarily but has and will consider later stage funding depending upon the merits of each deal structure.  The firm will consider a seed investment of $250k – $1 million for Seed.  Typical funding sizes for Series A & B are dependent upon the deal but generally $5 million and beyond. The firm is open to investing in companies worldwide and remain agnostic to space and disease.

The firm invests exclusively in the Life Science space and is looking for new investment opportunities in the therapeutics, medical devices, diagnostics, and selective digital health sectors. The firm is opportunistic in terms of sub-sectors and indications, including all classes of medical devices, as well as all phases of development for therapeutics.

The firm is open to all types of management teams but like to see highly motivated entrepreneurs who are looking to lead monumental healthcare change and with management teams that have serial startup drives with whom they can build long term partnerships. The firm is open to both leading, co-leading, or participating in syndicates depending on the company and deal structure.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The drug development company was founded in 2016 and is headquartered in the US. In 2016, they closed a $49 M fund to in-license 4-6 IND-ready assets and develop them through Phase 2b. After proof-of-concept is established, they will seek to exit. Roughly 90% of the fund will be used to fund development, with clinical trials carried out by the firm. They are particularly interested in therapeutics falling in the sectors of neuroscience and immunology.

The firm is seeking small molecules and biologics in the areas of neuroscience and immunology that can improve patient lives. They do not consider drugs for highly crowded spaces, for example oncology or disease-modifying drugs for Alzheimer’s. Levadopa-induced dyskinesia in Parkinson’s and ataxia have been areas of interest, and they will consider therapeutics for orphan and rare diseases. Drug platforms addressing self-similar indications/targets are also of interest.

The firm looks for IND-ready drugs that can be developed or re-purposed, and will conduct a thorough due diligence taking 6 months to a year. The opportunity should have a clear regulatory and development pathway and good prospects for an exit within 4 years of acquisition. With strong scientific backgrounds themselves, the firm respects the expertise of the innovators. They will work with founders to arrange a deal, and are open to negotiating option agreements.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The venture fund is based Spain and invests in early stage companies in the life sciences and Information Technology Sectors. The firm also invests in public companies through Convertible Bonds and secondary alternative markets. The firm also offers Venture Debt financing for private companies. Within Life Sciences, the firm invests in rounds of EUR 2-8 Million Seed and Series A rounds. The firm invests in Europe and North America.

In the life sciences, the fund focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. Outside of Therapeutics, the fund invests in companies that are revenue positive. The fund generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.

In therapeutic opportunities, the firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 8 million to reach a human Proof of Efficacy. In Spain, the firm typically leads investment rounds, and may syndicate

with other firms or leverage public funding. In North America, the firm seeks to co-invest in rounds led by top-tier Venture Capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The corporate venture fund is a sector-exclusive life sciences venture and growth equity fund focused on Asia, particularly China. Originally established in 2008 as a corporate venture subsidiary of a Big Pharma, the firm has since spun off and operates as an independent investment firm with offices in China and the US. The fund currently has ~$4.5B AUM and is investing from their fifth fund, a $750M fund that was closed in 2019. The firm is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round. With both USD and RMB funds, the firm focuses on China but also considers opportunities from USA.

In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders. The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A cross-border venture capital firm founded in 2014 is headquartered in Tokyo, Japan, with USA offices in Cambridge, MA and Seattle, WA. The firm recently closed its second fund at $95M. Its LPs includes some of the largest Japanese pharmaceutical companies. The firm has also launched a new life sciences incubator through which the firm seeks to nurture and advance early-stage therapeutic concepts and technologies with the goal of bringing them to a more mature stage of development. Typically, the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

An investment group based in New York is a wholly-owned subsidiary of a health system. The firm engages in strategic investments across a wide variety of sectors to benefit the health system. The firm invests at a set pace with ~2 surgery centers being invested in per year and are currently looking to diversify their portfolio. The firm tends to invest in seed and pre-revenue rounds as their allocation size is on the smaller side, but is interested in revenue generating opportunities with smaller rounds. The firm is currently in the process of diversifying their portfolio and prefers investing in companies that are related to the health system in some way such as companies that the health system is a customer of, companies that have done clinical studies within the health system, etc.

The firm is particularly interested in technologies that can help them increase the quality of care, decrease the cost of care, and increase the access of services to populations which have been historically denied. Beyond that though, the firm is rather opportunistic within the healthcare IT, medical

The firm requires that companies have some sort of relationship with the hospital system or have the endorsement of the senior management of the health system.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 2011 and based in Mumbai, India, a venture capital firm makes Seed to Series B investments across several key sectors including healthcare, fintech, consumer, AI, and life science services. The firm manages $200 million, and is investing from its second fund. While IvyCap focuses on India, the firm is looking for opportunities worldwide and has recently made an investment in the USA.

The firm will consider a wide variety of life science opportunities. The firm’s past investments have included pharma supply chain, AI, and healthcare services.

The firm seeks a strong and experienced management team, with a focus on entrepreneurs from elite educational institutions. The firm focuses on India and has a strong connection with the Indian Institutes of Technology, but looks worldwide for novel technology breakthroughs to invest in. The firm has also launched a Unified Innovation and Entrepreneurship Platform to incubate new startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.